Dr. Luc van Loon Joins Unicity's Scientific Advisory Board
An expert on protein and its role in nutrition,
Given his expertise on protein,
The USAB helps guide Unicity's product development and innovation. With the brightest minds working together, Unicity is able to further its mission to Make Life Better. Visit www.unicityscience.org to learn more.
About Unicity International: Unicity designs and produces innovative nutritional products that make healthy living doable in an on-the-go world. For over 30 years, Unicity has been a global leader in creating solutions that support better metabolic health, with the mission to Make Life Better for individuals worldwide. Learn more at www.unicity.com.
Media Contact:
CXO
(800) 864-2489
[email protected]
This transmission may be: (1) subject to the attorney-client privilege, (2) attorney work product, or (3) strictly confidential. If you are not the intended recipient of this message, you may not disclose, print, copy or disseminate this information. If you have received this in error, please reply and notify the sender (only) and delete the message. Unauthorized interception of this email is a violation of federal criminal law. This communication does not reflect an intention by the sender or the sender's client or principal to conduct a transaction or make any agreement by electronic means. Nothing contained in this message or in any attachment shall satisfy the requirements for a writing, and nothing contained herein shall constitute a contract or electronic signature under the Electronic Signatures in Global and National Commerce Act, any version of the Uniform Electronic Transactions Act or any other statute governing electronic transactions.
View original content to download multimedia:https://www.prnewswire.com/news-releases/dr-luc-van-loon-joins-unicitys-scientific-advisory-board-302188557.html
SOURCE Unicity International
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline
- Hafnia’s Q2 2026 Financial Results Presentation to Be Held on 28 August 2026
- Bekaert: Update on the Share Buyback Program and the Liquidity Agreement
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share